Depletion of central memory CD8
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
CD8-Positive T-Lymphocytes
/ drug effects
Dose-Response Relationship, Drug
Female
Humans
Immunotherapy
Killer Cells, Natural
/ drug effects
Male
Memory T Cells
/ drug effects
Middle Aged
Neoplasms
/ drug therapy
Receptors, CCR4
/ antagonists & inhibitors
T-Lymphocytes, Regulatory
/ drug effects
Treatment Outcome
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 12 2021
14 12 2021
Historique:
received:
07
09
2020
accepted:
29
11
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
11
1
2022
Statut:
epublish
Résumé
Regulatory T (Treg) cells are important negative regulators of immune homeostasis, but in cancers they tone down the anti-tumor immune response. They are distinguished by high expression levels of the chemokine receptor CCR4, hence their targeting by the anti-CCR4 monoclonal antibody mogamulizumab holds therapeutic promise. Here we show that despite a significant reduction in peripheral effector Treg cells, clinical responses are minimal in a cohort of patients with advanced CCR4-negative solid cancer in a phase Ib study (NCT01929486). Comprehensive immune-monitoring reveals that the abundance of CCR4-expressing central memory CD8
Identifiants
pubmed: 34907192
doi: 10.1038/s41467-021-27574-0
pii: 10.1038/s41467-021-27574-0
pmc: PMC8671535
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
CCR4 protein, human
0
Receptors, CCR4
0
mogamulizumab
YI437801BE
Banques de données
ClinicalTrials.gov
['NCT01929486']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7280Informations de copyright
© 2021. The Author(s).
Références
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
pubmed: 26412456
pmcid: 5705936
doi: 10.1056/NEJMoa1507643
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
pubmed: 25765070
pmcid: 4993154
doi: 10.1126/science.aaa1348
Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
pubmed: 21436444
Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).
pubmed: 25860605
pmcid: 5905674
doi: 10.1016/j.cell.2015.03.030
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
pubmed: 28187290
pmcid: 5391692
doi: 10.1016/j.cell.2017.01.017
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164 (1995).
pubmed: 7636184
Sakaguchi, S. Naturally arising Foxp3-expressing CD25
pubmed: 15785760
doi: 10.1038/ni1178
Sakaguchi, S., Miyara, M., Costantino, C. M. & Hafler, D. A. FOXP3
pubmed: 20559327
doi: 10.1038/nri2785
Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949 (2004).
pubmed: 15322536
doi: 10.1038/nm1093
Sato, E. et al. Intraepithelial CD8
pubmed: 16344461
pmcid: 1311741
doi: 10.1073/pnas.0509182102
Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295–307 (2006).
pubmed: 16557261
doi: 10.1038/nri1806
Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356–371 (2019).
pubmed: 30705439
doi: 10.1038/s41571-019-0175-7
Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128–3133 (1999).
pubmed: 10397255
Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25
pubmed: 10553041
Attia, P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L. & Rosenberg, S. A. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28, 582–592 (2005).
pubmed: 16224276
pmcid: 1533764
doi: 10.1097/01.cji.0000175468.19742.10
Jacobs, J. F. et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16, 5067–5078 (2010).
pubmed: 20736326
doi: 10.1158/1078-0432.CCR-10-1757
Abbas, A. K., Trotta, E., Simeonov, D. R., Marson, A. & Bluestone, J. A. Revisiting IL-2: Biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).
pubmed: 29980618
doi: 10.1126/sciimmunol.aat1482
Kim, J. M., Rasmussen, J. P. & Rudensky, A. Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191–197 (2007).
pubmed: 17136045
doi: 10.1038/ni1428
Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4
pubmed: 19464196
doi: 10.1016/j.immuni.2009.03.019
Sugiyama, D. et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3
pubmed: 24127572
pmcid: 3816454
doi: 10.1073/pnas.1316796110
Kurose, K. et al. Phase Ia study of FoxP3
pubmed: 26429981
doi: 10.1158/1078-0432.CCR-15-0357
Saito, T. et al. Phase Ib study of a humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors. Nagoya J. Med Sci. 83, 827–840 (2021).
pubmed: 34916725
pmcid: 8648528
Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12, 671–684 (2012).
pubmed: 22996603
pmcid: 6352980
doi: 10.1038/nrc3322
Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
pubmed: 31359002
pmcid: 6689255
doi: 10.1038/s41591-019-0522-3
Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708–712 (1999).
pubmed: 10537110
doi: 10.1038/44385
Shimazu, Y. et al. Hypomethylation of the Treg-specific demethylated region in FOXP3 is a hallmark of the regulatory T-cell subtype in adult T-cell leukemia. Cancer Immunol. Res. 4, 136–145 (2016).
pubmed: 26681759
doi: 10.1158/2326-6066.CIR-15-0148
Yamamoto, K. et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28, 1591–1598 (2010).
pubmed: 20177026
doi: 10.1200/JCO.2009.25.3575
Judge, S. J., Murphy, W. J. & Canter, R. J. Characterizing the dysfunctional NK cell: assessing the clinical relevance of exhaustion, anergy, and senescence. Front Cell Infect. Microbiol 10, 49 (2020).
pubmed: 32117816
pmcid: 7031155
doi: 10.3389/fcimb.2020.00049
Sato, T. et al. Mogamulizumab (Anti-CCR4) in HTLV-1-associated myelopathy. N. Engl. J. Med. 378, 529–538 (2018).
pubmed: 29414279
doi: 10.1056/NEJMoa1704827
Nishikawa, H., Jager, E., Ritter, G., Old, L. J. & Gnjatic, S. CD 4+CD25
pubmed: 15840697
doi: 10.1182/blood-2005-02-0607
Yoshie, O. & Matsushima, K. CCR4 and its ligands: from bench to bedside. Int Immunol. 27, 11–20 (2015).
pubmed: 25087232
doi: 10.1093/intimm/dxu079
Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290–1297 (2011).
pubmed: 21926977
pmcid: 3192229
doi: 10.1038/nm.2446
Wang, X. et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127, 2980–2990 (2016).
pubmed: 27118452
pmcid: 4911862
doi: 10.1182/blood-2015-12-686725
Ogura, M. et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J. Clin. Oncol. 32, 1157–1163 (2014).
pubmed: 24616310
doi: 10.1200/JCO.2013.52.0924
Kim, Y. H. et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 19, 1192–1204 (2018).
pubmed: 30100375
doi: 10.1016/S1470-2045(18)30379-6
De Simone, M. et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45, 1135–1147 (2016).
pubmed: 27851914
pmcid: 5119953
doi: 10.1016/j.immuni.2016.10.021
Plitas, G. et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45, 1122–1134 (2016).
pubmed: 27851913
pmcid: 5134901
doi: 10.1016/j.immuni.2016.10.032
Kamada, T. et al. PD-1
pubmed: 31028147
pmcid: 6525547
doi: 10.1073/pnas.1822001116
Saito, T. et al. Two FOXP3
pubmed: 27111280
doi: 10.1038/nm.4086
Sugiyama, E. et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci. Immunol. 5, eaav3937 (2020).
pubmed: 32005679
doi: 10.1126/sciimmunol.aav3937
Shaham, U. et al. Removal of batch effects using distribution-matching residual networks. Bioinformatics 33, 2539–2546 (2017).
pubmed: 28419223
pmcid: 5870543
doi: 10.1093/bioinformatics/btx196
Minoura, K., Abe, K., Maeda, Y., Nishikawa, H. & Shimamura, T. Model-based cell clustering and population tracking for time-series flow cytometry data. BMC Bioinforma. 20, 633 (2019).
doi: 10.1186/s12859-019-3294-3
Maeda, Y. et al. Detection of self-reactive CD8
pubmed: 25525252
doi: 10.1126/science.aaa1292
Calderon D. et al. Landscape of stimulation-responsive chromatin across diverse human immune cells. Nat. Genet. 51, 1494-1505 (2019), https://doi.org/10.1038/s41588-019-0505-9 .
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
pubmed: 22388286
pmcid: 3322381
doi: 10.1038/nmeth.1923
Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–W165 (2016).
pubmed: 27079975
pmcid: 4987876
doi: 10.1093/nar/gkw257
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982
pmcid: 2592715
doi: 10.1186/gb-2008-9-9-r137
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677
doi: 10.1093/bioinformatics/btt656
Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).
pubmed: 21221095
pmcid: 3346182
doi: 10.1038/nbt.1754
Birzele, F. et al. Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human. Nucleic Acids Res. 39, 7946–7960 (2011).
pubmed: 21729870
pmcid: 3185410
doi: 10.1093/nar/gkr444
Schmidl, C. et al. The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. Blood 123, e68–e78 (2014).
pubmed: 24671953
doi: 10.1182/blood-2013-02-486944
Merino, A. et al. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. J. Clin. Invest 129, 3770–3785 (2019).
pubmed: 31211698
pmcid: 6715389
doi: 10.1172/JCI125916